Quoin Pharmaceuticals reported net income of -$5.37M for the quarter ended Jun 2026. This income statement covers 27 quarters of results from Dec 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2017 | Jun2018 | Dec2018 | Jun2019 | Jun2020 | Dec2020 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 52.83M | 0.02M | 0.00M | 0.01M | 0.08M | 0.25M | 0.03M | 0.03M | 0.03M | 0.07M | 0.17M | 0.17M | 0.16M | 0.02M | 0.02M | 0.02M | 0.04M | 0.09M | 0.09M | ||||||||
| Operating items | |||||||||||||||||||||||||||
| Research & DevelopmentR&D | 0.26M | 1.01M | 0.59M | 0.73M | 0.75M | 0.83M | 1.09M | 0.63M | 0.76M | 0.83M | 0.89M | 0.59M | 1.08M | 1.05M | 2.37M | 2.05M | 2.28M | 3.10M | 3.43M | 3.63M | |||||||
| Selling, General & AdministrativeSG&A | 1.04M | 1.97M | 1.59M | 1.94M | 1.58M | 1.47M | 1.68M | 1.63M | 1.37M | 1.39M | 1.57M | 1.55M | 1.45M | 1.35M | 1.58M | 1.74M | 1.74M | 1.42M | 1.70M | 1.85M | |||||||
| Other Operating ExpensesOther Opex | -0.22M | ||||||||||||||||||||||||||
| Operating ExpensesOpex | 1.30M | 2.98M | 2.18M | 2.67M | 2.33M | 2.09M | 2.78M | 2.26M | 2.13M | 2.22M | 2.46M | 2.14M | 2.53M | 2.41M | 3.96M | 3.79M | 4.02M | 4.52M | 5.13M | 5.47M | |||||||
| Non-operating items | |||||||||||||||||||||||||||
| Non Operating Interest Expenses | -0.06M | ||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.02M | 0.08M | 0.15M | 0.19M | 0.20M | 0.14M | 0.10M | 0.15M | 0.10M | ||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.42M | 0.10M | -0.00M | 0.02M | -0.03M | 0.00M | 0.01M | -0.01M | -0.00M | 0.03M | -0.02M | 126.00 | -0.01M | 0.01M | 364.00 | -0.01M | 0.00M | ||||||||||
| Non Operating IncomeNon Op. Inc. | -0.10M | -8.84M | 0.49M | 0.08M | -0.70M | 0.08M | 0.17M | 0.15M | 0.20M | 0.17M | 0.13M | 0.16M | 0.18M | 0.09M | 0.14M | 0.10M | 0.07M | 0.17M | 0.13M | 0.10M | |||||||
| Net income details | |||||||||||||||||||||||||||
| Profit After TaxPAT | -1.40M | -11.82M | -1.68M | -2.67M | -3.03M | -2.00M | -2.60M | -2.11M | -1.93M | -2.05M | -2.33M | -1.97M | -2.35M | -2.31M | -3.81M | -3.70M | -3.95M | -4.31M | -5.00M | -5.37M | |||||||
| Net Income towards Common StockholdersNet Income | -1.40M | -11.82M | -3.09M | -2.00M | -1.93M | -2.05M | |||||||||||||||||||||
| Additional items | |||||||||||||||||||||||||||
| EPS (Basic) | -0.11 | -0.22 | -338.46 | -24.79 | -58.55 | -68.26 | |||||||||||||||||||||
| EPS (Diluted) | -0.04 | -0.22 | -338.46 | -24.79 | -58.55 | -68.26 | |||||||||||||||||||||
| Shares Outstanding | 12.27M | 52.83M | 0.02M | 0.00M | 0.01M | 0.08M | 0.25M | 0.03M | 0.03M | 0.03M | 0.07M | 0.17M | 0.17M | 0.16M | 0.02M | 0.02M | 0.02M | 0.04M | 0.09M | 0.09M | |||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 40.05M | 52.83M | 0.02M | 0.00M | 0.01M | 0.08M | 0.25M | 0.03M | 0.03M | 0.03M | 0.07M | 0.17M | 0.17M | 0.16M | 0.02M | 0.02M | 0.02M | 0.04M | 0.09M | 0.09M | |||||||
| Interest ExpensesInt Expense | -0.06M |